Ruxolitinib blocks Janus kinase (JAK) 1 and 2 signaling, a pathway involved in host defenses. A case is reported in which progressive multifocal leukoencephalopathy developed in a 75-year-old man with myelofibrosis a few weeks after the initiation of ruxolitinib.
No takes yet. Share an insight, caveat, or question.
Wathes et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: